Regeneron Pharmaceuticals, Inc. (REGN) is currently Undervalued by 54.67%

Regeneron Pharmaceuticals, Inc. (REGN) appears undervalued by approximately 54.67% based on our live valuation percent and intrinsic value estimate derived from DCF, P/E Multiple, and P/S Multiple models. Valuation can still differ across analyst models, growth expectations, and risk assumptions.

Upside (live) 54.67% (from live valuation API)
Confidence (live) 9.5/10 (Very High)

Confidence Score is based on the magnitude of upside or downside vs intrinsic value.

Fair value estimate

Unlock fair value

Current price

$649.81

Stock valuation checker

Search our company database (same as the site header). Choose a result or type a ticker and press Check valuation.

Explore Our Valuation Calculators

Intrinsic Value Calculator (DCF)ROE Calculator Stock Valuation Calculator

Why is Regeneron Pharmaceuticals, Inc. overvalued or undervalued?

For Regeneron Pharmaceuticals, Inc., intrinsic value ties fair value to sustainable cash generation; with the stock below that level, the snapshot reads as a discount versus fundamentals rather than a pure sentiment call.

Historical valuation for REGN shows cycles where multiples expanded and compressed; today’s positioning rhymes more with defensive pricing than the mid-range of its recent history.

Market expectations boil down to growth, risk, and return on capital—current levels leave more room for upside if execution is steady. Cross-check with live ratios when your API is connected.

Key metrics

P/E ratio: 10.3x
Revenue growth (TTM y/y): 27%
Profit margin: 35.0%
Fair value (model): Unlock

Next steps

Frequently asked questions — REGN

Is REGN overvalued right now?

A stock is overvalued when its market price sits above a reasonable fair value range. Use the live snapshot on this page for REGN, then validate with fundamentals and peer multiples.

What is Regeneron Pharmaceuticals, Inc.'s intrinsic value?

Our DCF, P/E Multiple, and P/S Multiple models estimate whether REGN trades above or below fair value. At $649.81, Regeneron Pharmaceuticals, Inc. currently looks undervalued on this snapshot. Tickerplace Pro unlocks the full dollar fair value estimate.

How is Regeneron Pharmaceuticals, Inc.'s intrinsic value calculated?

Tickerplace calculates REGN's fair value using Discounted Cash Flow (DCF), P/E Multiple, and P/S Multiple models. We compare the resulting intrinsic value estimate to the live market price to flag undervalued or overvalued positioning.

Is REGN undervalued right now?

Based on our 2026 valuation models, Regeneron Pharmaceuticals, Inc. (REGN) appears undervalued at $649.81 with about 54.7% upside to fair value. Treat this as a screen—verify fundamentals on the company profile.

Peers for REGN: open their overvalued / undervalued view.

Instant valuation answer